Recruitment closing soon: The BEYOND Clinical Trial- investigating the effects of Cannabidiol on seizure outcomes
The BEYOND Clinical Trial is a research study designed to explore the effects of Cannabidiol (Epidyolex®) on seizure outcomes in children and adults living with TSC. Co-designed by patients with epilepsy, the BEYOND trial is currently recruiting 20 participants in NSW and Canberra. From December, new referrals will no longer be accepted. If you or someone you care for could benefit from Epidyolex®, we encourage you to consider enrolling soon.
The good news is that rural and remote patients can participate in this trial, as it is administered from home, with no need for hospital visits.
About the Trial:
Online Appointments: All consultations are held virtually with a qualified neurologist.
Medicine Delivery: Epidyolex® is delivered directly to your home.
In-Home Clinical Assessments: Nurses will conduct all assessments in your home.
In-Home Blood Tests: All required blood tests are conducted in your home.
Inclusion Criteria: You (or your loved one living with TSC) may be eligible to participate if:
- The patient is 3 years of age or older; and
- Has a diagnosis of Developmental and Epileptic Encephalopathy (DEE).
- Experiences countable motor seizures.
- You agree to complete the procedures and provide informed consent.
If you’re interested in participating, or would like more information about the study, please contact Linda Truong at [email protected] or visit the trial website.
